Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma

12Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Cancer stem cells (CSCs) are a rare population with self-renewal and multipotent differentiation capacity, and reside among the more differentiated cancer cells. CSCs are associated with tumor recurrence, drug resistance and poor prognosis. The aim of this study was to determine the efficacy of napabucasin against HCC and elucidate the underlying molecular mechanisms. Napabucasin significantly decreased the viability of HCC cells in vitro by inducing apoptosis and cell cycle arrest. In addition, it suppressed CSC-related gene expression and spheroid formation in vitro, indicating depletion of CSCs. The anti-neoplastic effects of napabucasin was also evident in homograft tumor-bearing mouse models. Our findings provide the scientific basis of conducting clinical trials on napabucasin as a new therapeutic agent against HCC.

Cite

CITATION STYLE

APA

Li, Y., Han, Q., Zhao, H., Guo, Q., & Zhang, J. (2020). Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.597520

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free